Guggenheim analyst Seamus Fernandez downgraded Dice Therapeutics (DICE) to Neutral from Buy after Eli Lilly (LLY) agreed to buy the company in a deal that is expected to close in Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DICE:
- Dice Therapeutics downgraded to Hold from Buy at Stifel
- Dice Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Dice Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Dice Therapeutics downgraded to Hold from Buy at Canaccord
- Dice Therapeutics price target raised to $48 from $38 at Wells Fargo